Literature DB >> 19846849

Strict blood-pressure control and progression of renal failure in children.

Elke Wühl, Antonella Trivelli, Stefano Picca, Mieczyslaw Litwin, Amira Peco-Antic, Aleksandra Zurowska, Sara Testa, Augustina Jankauskiene, Sevinc Emre, Alberto Caldas-Afonso, Ali Anarat, Patrick Niaudet, Sevgi Mir, Aysin Bakkaloglu, Barbara Enke, Giovanni Montini, Ann-Margret Wingen, Peter Sallay, Nikola Jeck, Ulla Berg, Salim Caliskan, Simone Wygoda, Katharina Hohbach-Hohenfellner, Jiri Dusek, Tomasz Urasinski, Klaus Arbeiter, Thomas Neuhaus, Jutta Gellermann, Dorota Drozdz, Michel Fischbach, Kristina Möller, Marianne Wigger, Licia Peruzzi, Otto Mehls, Franz Schaefer.   

Abstract

BACKGROUND: Although inhibition of the renin-angiotensin system delays the progression of renal failure in adults with chronic kidney disease, the blood-pressure target for optimal renal protection is controversial. We assessed the long-term renoprotective effect of intensified blood-pressure control among children who were receiving a fixed high dose of an angiotensin-converting-enzyme (ACE) inhibitor.
METHODS: After a 6-month run-in period, 385 children, 3 to 18 years of age, with chronic kidney disease (glomerular filtration rate of 15 to 80 ml per minute per 1.73 m(2) of body-surface area) received ramipril at a dose of 6 mg per square meter of body-surface area per day. Patients were randomly assigned to intensified blood-pressure control (with a target 24-hour mean arterial pressure below the 50th percentile) or conventional blood-pressure control (mean arterial pressure in the 50th to 95th percentile), achieved by the addition of antihypertensive therapy that does not target the renin-angiotensin system; patients were followed for 5 years. The primary end point was the time to a decline of 50% in the glomerular filtration rate or progression to end-stage renal disease. Secondary end points included changes in blood pressure, glomerular filtration rate, and urinary protein excretion.
RESULTS: A total of 29.9% of the patients in the group that received intensified blood-pressure control reached the primary end point, as assessed by means of a Kaplan-Meier analysis, as compared with 41.7% in the group that received conventional blood-pressure control (hazard ratio, 0.65; confidence interval, 0.44 to 0.94; P=0.02). The two groups did not differ significantly with respect to the type or incidence of adverse events or the cumulative rates of withdrawal from the study (28.0% vs. 26.5%). Proteinuria gradually rebounded during ongoing ACE inhibition after an initial 50% decrease, despite persistently good blood-pressure control. Achievement of blood-pressure targets and a decrease in proteinuria were significant independent predictors of delayed progression of renal disease.
CONCLUSIONS: Intensified blood-pressure control, with target 24-hour blood-pressure levels in the low range of normal, confers a substantial benefit with respect to renal function among children with chronic kidney disease. Reappearance of proteinuria after initial successful pharmacologic blood-pressure control is common among children who are receiving long-term ACE inhibition. (ClinicalTrials.gov number, NCT00221845.) 2009 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19846849     DOI: 10.1056/NEJMoa0902066

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  255 in total

1.  The effect of a multidisciplinary care clinic on the outcomes in pediatric chronic kidney disease.

Authors:  Salma Ajarmeh; Lee Er; Genevieve Brin; Ognjenka Djurdjev; Janis M Dionne
Journal:  Pediatr Nephrol       Date:  2012-06-05       Impact factor: 3.714

Review 2.  Can vitamin D slow down the progression of chronic kidney disease?

Authors:  Rukshana Shroff; Mandy Wan; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2011-12-10       Impact factor: 3.714

3.  Why multidisciplinary clinics should be the standard for treating chronic kidney disease.

Authors:  Guido Filler; Steven E Lipshultz
Journal:  Pediatr Nephrol       Date:  2012-07-04       Impact factor: 3.714

4.  Pediatrics: blood pressure target for renoprotection in children.

Authors:  Robert H Mak; Joseph Flynn; George Bakris
Journal:  Nat Rev Nephrol       Date:  2010-02       Impact factor: 28.314

5.  Acute reversible changes of brachial-ankle pulse wave velocity in children with acute poststreptococcal glomerulonephritis.

Authors:  Mei-Ching Yu; Mei-Shiuan Yu; Meng-Kung Yu; Fan Lee; Wen-Hung Huang
Journal:  Pediatr Nephrol       Date:  2010-07-18       Impact factor: 3.714

Review 6.  Nephrology research--the past, present and future.

Authors:  Jürgen Floege; Robert H Mak; Bruce A Molitoris; Giuseppe Remuzzi; Pierre Ronco
Journal:  Nat Rev Nephrol       Date:  2015-09-29       Impact factor: 28.314

7.  Urologic care and progression to end-stage kidney disease: a Chronic Kidney Disease in Children (CKiD) nested case-control study.

Authors:  D I Chu; A G Abraham; G E Tasian; M R Denburg; M E Ross; S A Zderic; S L Furth
Journal:  J Pediatr Urol       Date:  2019-03-16       Impact factor: 1.830

Review 8.  Management of proteinuria in the transplanted patient.

Authors:  Tomáš Seeman
Journal:  Pediatr Nephrol       Date:  2014-08-27       Impact factor: 3.714

9.  Low Serum Bicarbonate and CKD Progression in Children.

Authors:  Denver D Brown; Jennifer Roem; Derek K Ng; Kimberly J Reidy; Juhi Kumar; Matthew K Abramowitz; Robert H Mak; Susan L Furth; George J Schwartz; Bradley A Warady; Frederick J Kaskel; Michal L Melamed
Journal:  Clin J Am Soc Nephrol       Date:  2020-05-28       Impact factor: 8.237

Review 10.  A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.

Authors:  Sonata Jodele; Benjamin L Laskin; Christopher E Dandoy; Kasiani C Myers; Javier El-Bietar; Stella M Davies; Jens Goebel; Bradley P Dixon
Journal:  Blood Rev       Date:  2014-11-28       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.